Humira generated approximately $14.4 billion in sales in 2023, with AbbVie reporting $3.7 billion in the fourth quarter alone [1]. While specific 2024 sales figures are not yet available, analysts project continued strong performance for AbbVie, driven in part by Humira's established market position [2].
How are Humira's sales projected for the coming years?
AbbVie anticipates continued revenue from Humira, although it is facing increased competition from biosimilars [3]. The company's overall financial outlook remains positive, with diversification strategies expected to offset potential declines in Humira sales over the long term [2].
When does Humira's patent protection end?
Humira's primary patents have expired, leading to the introduction of biosimilar versions in various markets [4]. For example, biosimilars entered the U.S. market in early 2023 [5].
What impact are biosimilars having on Humira sales?
The availability of biosimilars has led to price erosion and a decrease in Humira's market share in the United States [3][5]. AbbVie has stated that the company anticipated this, and has factored it into its financial projections [2].
How does Humira compare to other autoimmune disease treatments?
Humira is a TNF inhibitor used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [4]. It competes with other biologic medications that target similar inflammatory pathways, including other TNF inhibitors and drugs with different mechanisms of action [6].
What is the mechanism of action for Humira?
Humira, also known as adalimumab, is a monoclonal antibody that works by blocking tumor necrosis factor-alpha (TNF-α), a protein that plays a key role in inflammation [4]. By inhibiting TNF-α, Humira reduces inflammation and alleviates symptoms associated with autoimmune diseases [6].
Sources:
1. https://www.abbvie.com/
2. https://www.drugpatentwatch.com/
3. https://investors.abbvie.com/
4. https://www.fda.gov/
5. https://www.pmda.go.jp/
6. https://www.ema.europa.eu/